SAFETY DATA SHEET

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture	IMITREX INJECTION
Registration number	-
Synonyms	IMITREX INJECTION 4 MG/0.5 ML * IMITREX INJECTION 6 MG/0.5 ML * IMITREX STATDOSE SYSTEM * IMITREX STATDOSE PEN * IMITREX INJECTION CATRIDGE PACK * IMITREX SINGLE DOSE VIAL 6 MG * IMIGRAN SUBJECT TREATMENT PACK 0.5 ML * IMIGRAN SUBJECT REFILL PACK 0.5 ML * IMIGRAN INJECTION 12 MG/ML * IMIGRANE SYRINGE * SUMATRIPTAN SUCCINATE, FORMULATED PRODUCT
Issue date	06-November-2013
Version number	14
Revision date	06-November-2013
Supersedes date	17-June-2013

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses	Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.
Uses advised against	No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information Not applicable.

2.3. Other hazards Caution - Pharmaceutical agent.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
SUMATRIPTAN SUCCINATE	1.1 - < 1.7	103628-48-4 -	-	-	

Classification: **DSD:** Repr. Cat. 3;R63, R52/53

CLP: Repr. 2;H361d, Aquatic Chronic 3;H412

Other components below reportable levels >98.0

CLP: Regulation No. 1272/2008.
DSD: Directive 67/548/EEC.
M: M-factor
vPvB: very persistent and very bioaccumulative substance.
PBT: persistent, bioaccumulative and toxic substance.
#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.

4.1. Description of first aid measures

Inhalation In case of accident by inhalation: remove casualty to fresh air and keep at rest. If breathing is difficult, trained personnel should give oxygen. If not breathing, give artificial respiration. Get medical attention immediately.

Skin contact Immediately flush with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Remove and isolate contaminated clothing and shoes. Get medical attention immediately.

Eye contact In the case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

Ingestion Rinse mouth. Call a physician or poison control centre immediately. Only induce vomiting at the instruction of medical personnel. Never give anything by mouth to an unconsious person.

4.2. Most important symptoms and effects, both acute and delayed The following adverse effects have been noted with therapeutic use of this material: dizziness; drowsiness; abnormal nervous system sensations; difficult or irregular breathing; nausea; vomiting; feelings of heaviness or pressure; weakness; fatigue.

4.3. Indication of any immediate medical attention and special treatment needed No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the local poison control information centre.

SECTION 5: Firefighting measures

General fire hazards This product is non-flammable.

5.1. Extinguishing media

Suitable extinguishing media Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media Not available.

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures Move containers from fire area if you can do so without risk.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate personal protective equipment. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the MSDS.

6.2. Environmental precautions Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up

Large Spills: Stop the flow of material, if this is without risk. Dike the spilled material, where this is possible. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Prevent product from entering drains. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills in original containers for re-use.

6.4. Reference to other sections

For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Avoid prolonged exposure. Provide adequate ventilation. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. Avoid release to the environment. Do not empty into drains.

7.2. Conditions for safe storage, including any incompatibilities

Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Store away from incompatible materials (see Section 10 of the MSDS).

7.3. Specific end use(s)

Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Type	Value	Note
SUMATRIPTAN SUCCINATE (CAS 103628-48-4)	15 MIN STEL	100 mcg/m3	
	8 HR TWA	50 mcg/m3	
	OHC	3	Reproductive hazard

Biological limit values

No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures

Follow standard monitoring procedures.

Derived No Effect Level (DNEL)

Not available.

Predicted no effect concentrations (PNECs)

Not available.

8.2. Exposure controls

Appropriate engineering controls

An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

Individual protection measures, such as personal protective equipment

General information

Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection

Wear safety glasses with side shields (or goggles). (eg. EN 166) Wear a full-face respirator, if needed.

Skin protection

- Hand protection

The choice of an appropriate glove does not only depend on its material but also on other quality features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. With respect to the above precautions select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).

- Other

Not normally needed.

Respiratory protection

No personal respiratory protective equipment normally required.

Thermal hazards

Wear appropriate thermal protective clothing, when necessary.

Hygiene measures

When using, do not eat, drink or smoke. Wash hands after handling and before eating. An occupational/industrial hygiene monitoring method has been developed for this material. For advice on suitable monitoring methods, seek guidance from a qualified environment, health and safety professional.

Environmental exposure controls

Hazard guidance and control recommendations	Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state	Liquid.
Form	Solution.
Colour	Not available.
Odour	Not available.
Odour threshold	Not available.
pH	4.5 - 5
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.
9.2. Other information	No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.
10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Contact with incompatible materials.
10.5. Incompatible materials	Strong oxidising agents.
10.6. Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information	Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause adverse effects.

Information on likely routes of exposure

Ingestion	May be harmful if swallowed.
Inhalation	Health injuries are not known or expected under normal use.
Skin contact	Health injuries are not known or expected under normal use.
Eye contact	Health injuries are not known or expected under normal use.

Symptoms The following adverse effects have been noted with therapeutic use of this material: dizziness; drowsiness; abnormal nervous system sensations; difficult or irregular breathing; nausea; vomiting; feelings of heaviness or pressure; weakness; fatigue.

11.1. Information on toxicological effects

Acute toxicity May be harmful if swallowed.

Components	Species	Test results
SUMATRIPTAN SUCCINATE (CAS 103628-48-4)		
Acute		
Oral		
LD50	Mouse	> 1500 mg/kg
	Rat	> 2000 mg/kg
Chronic		
Oral		
NOAEL	Rat	5 mg/kg/day, 18 months
TD	Rat	>= 50 mg/kg/day
Subchronic		
Oral		
TD	Dog	<= 50 mg/kg/day, 60 weeks

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Serious eye damage/eye irritation Health injuries are not known or expected under normal use.

Eye

SUMATRIPTAN SUCCINATE
OECD 405
Result: Mild irritant
Species: Rabbit

Respiratory sensitisation Not established.

Skin sensitisation This product is not expected to cause skin sensitisation.

Sensitisation

SUMATRIPTAN SUCCINATE
Topical
Result: negative
Species: Guinea pig

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are mutagenic or genotoxic.

Germ cell mutagenicity

Mutagenicity

SUMATRIPTAN SUCCINATE
<= 1000 mg/kg Micronucleus Test
Result: negative
Species: Rat
Ames, GLP
Result: negative
Bacterial Fluctuation Test
Result: negative
Chromosomal Aberration Assay In Vitro, GLP
Result: negative
HPRT gene mutation in human lymphocytes
Result: negative
WHO Nitrosation Assay
Result: negative
Yeast Mutation Assay
Result: negative

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

SUMATRIPTAN SUCCINATE
10 - 160 mg/kg/day
Result: negative
Species: Mouse
10 - 160 mg/kg/day
Result: negative
Species: Rat

Reproductive toxicity Components in this product have been shown to cause birth defects and reproductive disorders in laboratory animals.

Reproductive toxicity

Reproductivity

SUMATRIPTAN SUCCINATE	100 mg/kg/day Fertility Result: Reduced success of insemination. Species: Rat 1000 mg/kg/day Pre- and Post-natal development Result: Maternal toxicity; adverse foetal effects 50 mg/kg/day Embryo-foetal development- Oral Result: NOAEL Species: Rabbit 60 mg/kg/day Embryo-foetal development - Oral Result: NOAEL Species: Rabbit >= 100 mg/kg/day Embryo-foetal development - Oral Result: Maternal toxicity; adverse foetal effects Species: Rat >= 100 mg/kg/day Embryo-foetal development- Oral Result: Maternal toxicity; adverse foetal effects Species: Rabbit

Specific target organ toxicity - single exposure	Circulatory system.
Specific target organ toxicity - repeated exposure	None known.
Aspiration hazard	Due to partial or complete lack of data the classification is not possible.
Mixture versus substance information	Not available.
Other information	None known.

SECTION 12: Ecological information

12.1. Toxicity Contains a substance which causes risk of hazardous effects to the environment.

Components		Species	Test results
SUMATRIPTAN SUCCINATE (CAS 103628-48-4)			
Aquatic			
Acute			
Activated Sludge Respiration	IC50	Residential sludge	> 750 mg/l, 3 hours, OECD 209
Algae	EC50	Green algae (Scenedesmus subspicatus)	36 mg/l, 72 hours, OECD 201
	NOEC	Green algae (Scenedesmus subspicatus)	12.5 mg/l, 72 hours
Crustacea	EC50	Water flea (Daphnia pulex)	290 mg/l, 48 hours, Static test, OECD 202
	NOEC	Water flea (Daphnia pulex)	200 mg/l, 48 hours
Fish	EC50	Rainbow trout (Juvenile Oncorhyncus mykiss)	> 100 mg/l, 96 hours, OECD 203
	NOEC	Rainbow trout (Juvenile Oncorhyncus mykiss)	100 mg/l, 96 hours
Chronic			
Crustacea	LOEC	Water flea (Ceriodaphnia dubia)	100 mg/l, 8 days, Static renewal test, EPA Method 1002
	NOEC	Daphnia	32 mg/l, 8 days

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Persistence and degradability

Photolysis

UV/visible spectrum wavelength

SUMATRIPTAN SUCCINATE	290 nm

Hydrolysis

Half-life (Hydrolysis-neutral)

SUMATRIPTAN SUCCINATE	> 1 years Measured

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

SUMATRIPTAN SUCCINATE	100 %, 16 days Modified Zahn-Wellens, primary biodegradation, loss of parent., Activated sludge 17 %, 28 days Modified Zahn-Wellens, DOC removal., Activated sludge

Percent degradation (Aerobic biodegradation-ready)

SUMATRIPTAN SUCCINATE	1 %, 28 days

Percent degradation (Aerobic biodegradation-soil)

SUMATRIPTAN SUCCINATE	32 - 40 %, 64 days, Soil

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

SUMATRIPTAN SUCCINATE	0.93 (Measured).

12.4. Mobility in soil

Adsorption

Soil/sediment sorption - log Koc

SUMATRIPTAN SUCCINATE	3.52 - 3.57 Measured

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

EU waste code The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with local/regional/national/international regulations.

Special precautions Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations	The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.
National regulations	Follow national regulation for work with chemical agents.
15.2. Chemical safety assessment	No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations	Not available.
References	GSK Hazard Determination
Information on evaluation method leading to the classification of mixture	The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.
Full text of any statements or R-phrases and H-statements under Sections 2 to 15	R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R63 Possible risk of harm to the unborn child. H361d Suspected of damaging the unborn child. H412 Harmful to aquatic life with long lasting effects.
Revision information	SECTION 4: First aid measures: Ingestion SECTION 8: Exposure controls/personal protection: Respiratory protection SECTION 13: Disposal considerations: Disposal methods/information
Training information	Follow training instructions when handling this material.
Disclaimer	The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.